These results suggest that ALB mitigates inflammation and ameliorates liver fibrosis by targeting the CXCL12/CXCR4 axis, a finding confirmed by experiments using the CXCR4 inhibitor AMD3100 in CCl4-treated mice. The gene discussed is CXCR4; the disease is Hepatic fibrosis.